Weight Loss Drugs or Exercise and Nutrition?

Most debates about obesity focus on "weight loss." But the real question is: what is the healthiest way to change physiology long-term?

Exercise is not "just calories" — it rewires biology

Regular training drives adaptations through pathways like PGC-1α (mitochondrial biogenesis and endurance capacity) and mTOR (muscle protein synthesis and strength). The downstream benefits are broader than weight alone:

• Improved insulin sensitivity

• Better cardiovascular function and blood pressure

• Reduced inflammation

• Improved sleep, mood, and functional capacity

• Greater muscle and bone health (especially important as we age)
  

These adaptations are typically durable when you keep moving — not because they suppress appetite, but because they change how the body runs.

GLP-1 / incretin drugs work powerfully, but they are different

Medications like semaglutide (Ozempic/Wegovy) and related GLP-1 therapies can be life-changing for many people, particularly those with serious obesity or metabolic disease. They help primarily by reducing appetite and improving glucose regulation.

But here's the key clinical tension:The strongest benefits often track with ongoing treatment. When the medication stops, many people regain weight unless lifestyle strategies and body composition protections are already in place.

A few important caveats:GLP-1 medications significantly increase the risk of pancreatitis (or in those with prior pancreatic inflammation), severe gastrointestinal disease or prior severe GI intolerance, active gallbladder disease or history of gallstones/cholecystitis, and significant kidney disease — especially if dehydrated or experiencing vomiting/diarrhoea. GLP-1–related GI side effects can cause dehydration, which can worsen kidney function. This is particularly important in CKD, prior AKI, or frail patients.

GLP-1s commonly reduce appetite. In people who are already underweight, malnourished, or at risk of anorexia/bulimia, the risk is worsening nutritional status, muscle loss, and frailty.

The long-term question should be: "How do we maintain health?"

If the goal is healthy living, then we should ask:

a) Are we treating obesity as a chronic metabolic condition? This may require lifelong medication for many.

b) Or should we reserve pharmacotherapy more narrowly for those with medical need (e.g. severe obesity, obesity with complications), using it as a time-limited tool while sustainable behaviour change builds? Probably the most difficult path in this day and age.

My position (to invite debate):"Weight loss drugs should be limited in time and targeted to serious obesity, with exercise and nutrition used as the long-term foundation."

I'm not arguing that GLP-1s have no place. I'm arguing they should not become the default "set-and-forget" solution for people who don't have a medical indication.

My hypothesis comes against the backdrop of the news that the NHS will soon make this freely available. The same thing happened when Type 2 diabetes medication Metformin et al. was invented — individuals didn't change their habits and behaviours, and instead obesity and Type 2 diabetes have continued to rise. My argument is that we need more stick and less carrot...

If we want the benefits beyond the scales — strength, cardiovascular resilience, insulin sensitivity, and lasting function — then training should be central, not optional.

What do you think?Should GLP-1 therapy be time-limited for most, reserved for severe obesity, or is long-term medication appropriate for a larger group?

I'd genuinely like to hear different evidence-based views.

"In my view, the body doesn't learn habits from injections — it learns them from training, nutrition, and consistency. Medication can help start the process, but it can't replace physiology and lifestyle long-term."